Abstract:Biological molecules are increasingly becoming a part of the therapeutics portfolio that has been either recently approved for marketing or those that are in the pipeline of several biotech and pharmaceutical companies. This is largely based on their ability to be highly specific relative to small molecules. However, by virtue of being a large protein, and having a complex structure with structural variability arising from production using recombinant gene technology in cell lines, such therapeutics run the risk of being recognized as foreign by a host immune system. In the context of immune-mediated adverse effects that have been documented to biological drugs thus far, including infusion reactions, and the evolving therapeutic platforms in the pipeline that engineer different functional modules in a biotherapeutic, it is critical to understand the interplay of the adaptive and innate immune responses, the pathophysiology of immunogenicity to biological drugs in instances where there have been immune-mediated adverse clinical sequelae and address technical approaches for their laboratory evaluation. The current paradigm in immunogenicity evaluation has a tiered approach to the detection and characterization of anti-drug antibodies (ADAs) elicited in vivo to a biotherapeutic; alongside with the structural, biophysical, and molecular information of the therapeutic, these analytical assessments form the core of the immunogenicity risk assessment. However, many of the immune-mediated adverse effects attributed to ADAs require the formation of a drug/ADA immune complex (IC) intermediate that can have a variety of downstream effects. This review will focus on the activation of potential immunopathological pathways arising as a consequence of circulating as well as cell surface bound drug bearing ICs, risk factors that are intrinsic either to the therapeutic molecule or to the host that might predispose to IC-mediated effects, and review the recent literature on prevalence and intensity of established examples of type II and III hypersensitivity reactions that follow the administration of a biotherapeutic. Additionally, we propose methods for the study of immune parameters specific to the biology of ICs that could be of use in conjunction with the detection of ADAs in circulation.

Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey

Anti-drug Antibody Validation Testing and Reporting Harmonization

Immunogenicity assessment strategy for a chemically modified therapeutic protein in clinical development

Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective

Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical Trials

Immunogenicity Risk Assessment of Process-related Impurities in an Engineered T cell Receptor Cellular Product

Immunotoxicant screening and prioritization in the twenty-first century

Neutralizing Antibody Validation Testing and Reporting Harmonization

Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs)

The challenges for implementing Good Clinical Practices in the bioanalytical laboratory: a discussion paper from the European Bioanalysis Forum

Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).